Neuren Pharmaceuticals Limited (ASX:NEU)
Australia flag Australia · Delayed Price · Currency is AUD
11.48
+0.08 (0.70%)
At close: Mar 18, 2026

Neuren Pharmaceuticals Income Statement

Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
64.63136.73231.9314.55-
Other Revenue
0.0280.110.020.863.2
64.65216.83231.9415.423.2
Revenue Growth (YoY)
-70.19%-6.51%1404.46%382.23%345.89%
Cost of Revenue
36.3932.9726.7512.719.52
Gross Profit
28.26183.86205.192.71-6.32
Selling, General & Admin
6.224.75.953.441.91
Operating Expenses
6.224.75.953.441.91
Operating Income
22.04179.16199.25-0.73-8.23
Interest & Investment Income
12.1611.015.690.390.04
Currency Exchange Gain (Loss)
8.03-7.242.431.230.4
Other Non Operating Income (Expenses)
-3.3--2.23-0.7-
EBT Excluding Unusual Items
38.93182.94205.140.18-7.79
Pretax Income
38.93182.94205.140.18-7.79
Income Tax Expense
8.4940.948.06--
Net Income
30.44142.04157.080.18-7.79
Net Income to Common
30.44142.04157.080.18-7.79
Net Income Growth
-78.57%-9.57%85270.11%--
Shares Outstanding (Basic)
128128127126118
Shares Outstanding (Diluted)
131131131129119
Shares Change (YoY)
-0.01%0.01%1.44%8.76%10.71%
EPS (Basic)
0.241.111.240.00-0.07
EPS (Diluted)
0.231.091.200.00-0.07
EPS Growth
-78.57%-9.58%120020.00%--
Free Cash Flow
125.39-11.28184.893.58-9.98
Free Cash Flow Per Share
0.96-0.091.410.03-0.08
Gross Margin
43.71%84.80%88.47%17.55%-197.65%
Operating Margin
34.09%82.63%85.90%-4.75%-257.52%
Profit Margin
47.08%65.51%67.72%1.19%-243.79%
Free Cash Flow Margin
193.95%-5.20%79.71%23.22%-312.17%
EBITDA
22.06179.18199.26-0.72-8.23
EBITDA Margin
34.13%82.64%85.91%-4.68%-257.27%
D&A For EBITDA
0.020.020.020.010.01
EBIT
22.04179.16199.25-0.73-8.23
EBIT Margin
34.09%82.63%85.90%-4.75%-257.52%
Effective Tax Rate
21.82%22.36%23.43%--
Revenue as Reported
84.84227.85240.0617.033.64
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.